Select a medication above to begin.
Breyanzi
lisocabtagene maraleucel
Black Box Warnings .
Appropriate Use
restricted distribution program (Breyanzi REMS) due to cytokine release syndrome (CRS) and neurological toxicity risk; admin. only at certified healthcare facility w/ on-site, immediate access to tocilizumab, and a minimum of 2 doses of tocilizumab for each pt w/in 2h after tx if needed; 1-866-340-7332 or www.BreyanziREMS.com for more information
Cytokine Release Syndrome
incl. fatal or life-threatening rxn, occurred; do not admin. if active infection or inflammatory disorders; treat severe or life-threatening CRS w/ tocilizumab +/- corticosteroids; monitor pts daily for at least 7 days post-infusion at certified healthcare facility, then monitor s/sx for at least 4wk after tx w/in proximity of certified healthcare facility; counsel pts on s/sx and to seek immediate medical attention if they occur at any time
Neurological Toxicities
incl. fatal or life-threatening rxn, occurred, incl. concurrently w/ CRS, after CRS resolution, or in the absence of CRS; provide supportive care and/or corticosteroids as needed; monitor pts daily for at least 7 days post-infusion at certified healthcare facility, then monitor s/sx for at least 4wk after tx w/in proximity of certified healthcare facility; counsel pts on s/sx and to seek immediate medical attention if they occur at any time
Secondary Hematological Malignancies
incl. T-cell malignancies, have occurred; monitor life-long; contact Bristol-Myers Squibb at 1-888-805-4555 to report malignancy occurrence and obtain instructions on pt sample collection
Adult Dosing .
Dosage forms: INJ
Restricted Distribution in US
- [1-866-340-7332 or www.BreyanziREMS.com for more info]
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, prophylactic antimicrobials, and dosing
large B-cell lymphoma, relapsed or refractory
- [2nd-line tx]
- Dose: 90-110 x10^6 chimeric antigen receptor (CAR)-positive viable T-cells IV x1; Start: 2-7 days after completing lymphodepleting combo chemo regimen cyclophosphamide + fludarabine; Info: for pts w/ diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B
- [3rd-line and subsequent tx]
- Dose: 50-110 x10^6 chimeric antigen receptor (CAR)-positive viable T-cells IV x1; Start: 2-7 days after completing lymphodepleting combo chemo regimen cyclophosphamide + fludarabine; Info: for pts w/ diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B
CLL/SLL, relapsed or refractory
- [90-110 x10^6 chimeric antigen receptor (CAR)-positive viable T-cells IV x1]
- Start: 2-7 days after completing lymphodepleting combo chemo regimen cyclophosphamide + fludarabine; Info: for pts who have received at least 2 prior tx, incl. a BTK inhibitor and a BCL-2 inhibitor
follicular lymphoma, relapsed or refractory
- [90-110 x10^6 chimeric antigen receptor (CAR)-positive viable T-cells IV x1]
- Start: 2-7 days after completing lymphodepleting combo chemo regimen cyclophosphamide + fludarabine; Info: for pts who have received at least 2 prior tx
mantle cell lymphoma, relapsed or refractory
- [90-110 x10^6 chimeric antigen receptor (CAR)-positive viable T-cells IV x1]
- Start: 2-7 days after completing lymphodepleting combo chemo regimen cyclophosphamide + fludarabine; Info: for pts who have received at least 2 prior tx, incl. a BTK inhibitor
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- pregnancy
- infection, active
- inflammatory disorder
- GVHD, active
- chemotherapy-associated serious rxn, unresolved
- avoid: blood donation indefinitely
- avoid: organ donation indefinitely
- avoid: tissue donation indefinitely
- avoid: cell donation indefinitely
- caution: hypersensitivity to DMSO
- caution: pts of childbearing potential
- caution: HBV carriers
Drug Interactions .
Overview
lisocabtagene maraleucel
CAR T cell immunotherapy
- immunomodulatory effects (other)
- immunosuppressive oncologic agent
- lowers seizure threshold
- myelosuppressive oncologic agent
Contraindicated
- adenovirus vaccine, live
- BCG live intravesical
- chikungunya vaccine, live
- cholera vaccine, live
- dengue vaccine, live
- influenza nasal vaccine, live
- measles/mumps/rubella vaccine, live
- rotavirus vaccine, live
- smallpox vaccine, live
- talimogene laherparepvec
- typhoid vaccine, live
- varicella vaccine, live
- yellow fever vaccine, live
Avoid/Use Alternative
- abrocitinib
- aldesleukin
- amifampridine
- anifrolumab
- anti-thymocyte globulin
- azathioprine
- basiliximab
- belatacept
- betamethasone
- budesonide
- budesonide rectal
- chloramphenicol
- cladribine oral
- cortisone
- cyclosporine
- deferiprone
- deflazacort
- deuruxolitinib
- dexamethasone
- etrasimod
- everolimus
- fexinidazole
- fludrocortisone
- ganciclovir
- hydrocortisone
- iohexol
- lymphocyte immune globulin, anti-thymocyte globulin
- methylprednisolone
- mycophenolate mofetil
- mycophenolic acid
- natalizumab
- palifermin
- penicillamine
- pimecrolimus topical
- prednisolone
- prednisone
- primaquine
- rabies vaccine
- radium Ra 223 dichloride
- ritlecitinib
- ropeginterferon alfa-2b
- ruxolitinib topical
- sirolimus
- tacrolimus
- triamcinolone
- valganciclovir
- vamorolone
- voclosporin
Monitor/Modify Tx
- albendazole
- alemtuzumab
- allopurinol
- anthrax vaccine
- asenapine
- atidarsagene autotemcel
- auranofin
- balsalazide
- baricitinib
- benznidazole
- betibeglogene autotemcel
- bupropion
- chikungunya vaccine
- cidofovir
- clozapine
- colchicine
- COVID-19 vaccine
- cyclophosphamide
- dapsone
- deferasirox
- dexrazoxane
- diphtheria/tetanus vaccine
- diphtheria/tetanus/pertussis vaccine
- ebola vaccine, live
- efbemalenograstim alfa
- eflapegrastim (G-CSF)
- elivaldogene autotemcel
- exagamglogene autotemcel
- filgrastim (G-CSF)
- flucytosine
- fluphenazine
- foscarnet
- fostamatinib
- givinostat
- Haemophilus b vaccine
- hepatitis A vaccine
- hepatitis B vaccine
- human papillomavirus vaccine
- hydroxychloroquine
- hydroxyurea
- iloperidone
- influenza H5N1 vaccine
- influenza vaccine
- interferon beta 1a
- interferon beta 1b
- interferon gamma 1b
- iopamidol
- Japanese encephalitis vaccine
- leflunomide
- linezolid
- lonafarnib
- lovotibeglogene autotemcel
- lumateperone
- meningococcal vaccine
- mercaptopurine
- mesalamine
- mesalamine rectal
- methotrexate
- olsalazine
- pegfilgrastim (G-CSF)
- peginterferon alfa 2a
- peginterferon beta 1a
- pentamidine
- pneumococcal vaccine
- poliovirus vaccine
- proguanil
- pyrimethamine
- respiratory syncytial virus vaccine
- ribavirin
- rifabutin
- rituximab
- sargramostim (GM-CSF)
- sarilumab
- satralizumab
- sipuleucel-T
- smallpox/mpox vaccine, live
- stiripentol
- succimer
- sulfasalazine
- teplizumab
- teriflunomide
- thalidomide
- tick-borne encephalitis vaccine
- tocilizumab
- tofacitinib
- trimethoprim
- typhoid vaccine
- upadacitinib
- valproic acid
- zidovudine
Caution Advised
- abatacept
- acetazolamide
- adalimumab
- anakinra
- avacopan
- beclomethasone inhaled
- beclomethasone nasal
- belimumab
- bimekizumab
- brivaracetam
- brodalumab
- budesonide inhaled
- budesonide nasal
- busulfan
- canakinumab
- cannabidiol
- carbamazepine
- cenobamate
- certolizumab pegol
- chlorambucil
- clobazam
- clobetasol ophthalmic
- clomipramine
- clonazepam
- clorazepate
- corticotropin
- crovalimab
- danicopan
- deucravacitinib
- dexamethasone ophthalmic
- diazepam
- difluprednate ophthalmic
- dimethyl fumarate
- diroximel fumarate
- dupilumab
- eculizumab
- efgartigimod alfa
- emapalumab
- eslicarbazepine acetate
- etanercept
- ethosuximide
- felbamate
- fenfluramine
- fingolimod
- flunisolide nasal
- fluocinolone intravitreal
- fluorometholone ophthalmic
- fluticasone furoate
- fluticasone propionate
- fosphenytoin
- gabapentin
- ganaxolone
- golimumab
- guselkumab
- hydrocortisone ophthalmic
- inebilizumab
- infliximab
- iptacopan
- ixekizumab
- lacosamide
- lamotrigine
- lebrikizumab
- levetiracetam
- lindane topical
- lorazepam
- loteprednol ophthalmic
- magnesium citrate
- methsuximide
- midazolam
- mirikizumab
- mitoxantrone
- mometasone implant
- mometasone inhaled
- mometasone nasal
- monomethyl fumarate
- nadofaragene firadenovec intravesical
- nipocalimab
- ocrelizumab
- ofatumumab
- oxcarbazepine
- ozanimod
- pegcetacoplan
- perampanel
- phenobarbital
- phenytoin
- polyethylene glycol
- polyethylene glycol/electrolytes
- ponesimod
- pozelimab
- prednisolone ophthalmic
- pregabalin
- primidone
- promethazine
- ravulizumab
- rilonacept
- risankizumab
- rozanolixizumab
- rufinamide
- secukinumab
- siltuximab
- siponimod
- sodium picosulfate
- spesolimab
- sulfate bowel prep
- sutimlimab
- tezepelumab
- tiagabine
- tildrakizumab
- topiramate
- tralokinumab
- tramadol
- treosulfan
- tuberculin purified protein derivative
- ublituximab
- ustekinumab
- vedolizumab
- vigabatrin
- vilobelimab
- zilucoplan
- zonisamide
Adverse Reactions .
Serious Reactions
- cytokine release syndrome
- hypotension, severe
- fever
- hypoxia
- cardiac arrest
- cardiac failure
- respiratory failure
- pulmonary edema
- capillary leak syndrome
- HTN
- arrhythmia
- renal failure
- neurotoxicity, severe
- immune effector cell-assoc. neurotoxicity syndrome
- encephalopathy
- seizures
- aphasia
- cerebral edema
- hypersensitivity rxn, severe
- anaphylaxis
- infection, serious
- febrile neutropenia
- HBV reactivation
- neutropenia, incl. prolonged
- thrombocytopenia, incl. prolonged
- anemia, incl. prolonged
- hypogammaglobulinemia, incl. prolonged
- lymphopenia
- hemophagocytic lymphohistiocytosis
- macrophage activation syndrome
- thrombosis
- secondary malignancy
- T-cell malignancy
- chimeric antigen receptor (CAR)-positive lymphoma
Common Reactions
- cytokine release syndrome
- fatigue
- musculoskeletal pain
- infection
- neurotoxicity
- headache
- nausea
- thrombocytopenia
- fever
- encephalopathy
- neutropenia
- diarrhea
- constipation
- appetite decr.
- hypotension
- edema
- dizziness
- tachycardia
- cough
- tremor
- abdominal pain
- dyspnea
- vomiting
- insomnia
- rash
- HTN
- hypogammaglobulinemia
- motor dysfxn
- hemorrhage
- renal failure
- rigors
- peripheral neuropathy
- delirium
- aphasia
- anxiety
- thrombosis
- anemia
- ataxia
- febrile neutropenia
- hypoxia
- sepsis
- visual disturbance
- arrhythmia
- lymphocytes decr.
Safety/Monitoring .
Monitoring Parameters
screening for HBV, HCV, HIV before leukapheresis; pregnancy test at baseline; CBC, s/sx infection before and after infusion; IgG levels after infusion; s/sx cytokine release syndrome, neurological toxicities daily for at least 7 days post-infusion at certified healthcare facility, then for at least 4wk after tx w/in proximity of certified healthcare facility
Pregnancy/Lactation .
Pregnancy
Clinical Summary
avoid use during pregnancy; no human or animal data available; possible risk of B-cell lymphocytopenia and hypogammaglobulinemia based on drug's mechanism of action
Individuals of Reproductive Potential
obtain pregnancy test before tx start; avoid pregnancy by using effective contraception during and after tx in female pts
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: other; CYP450: unknown
Excretion: unknown; Half-life: unknown
Subclass: Immunotherapy, CAR T-Cells ; Immunotherapy, CD19 Inhibitors
Mechanism of Action
binds to CD19-expressing cells via chimeric antigen receptor (CAR)-positive autologous T-cells, inducing T-cell expansion, activation, and proliferation, and eliminating CD19-expressing cells
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.